APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urology Drugs Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchUrology Drugs Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Urology Drugs Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Urology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urology Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Urology Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Urology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urology Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urology Drugs market include Endo, Astellas, Tolmar and GP Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urology Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urology Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urology Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Urology Drugs Segment by Company

Endo

Astellas

Tolmar

GP Pharm

Urology Drugs Segment by Type

Α (alpha) Blockers

5 α-reductase Inhibitors

Urology Drugs Segment by Application

Hospital

Clinic

Others

Urology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Urology Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urology Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urology Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Urology Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urology Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urology Drugs industry.

Chapter 3: Detailed analysis of Urology Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urology Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urology Drugs Industry Trends Table 2. Urology Drugs Industry Drivers Table 3. Urology Drugs Industry Opportunities and Challenges Table 4. Urology Drugs Industry Restraints Table 5. Global Urology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urology Drugs Revenue Share by Company (2021-2026) Table 7. Global Urology Drugs Sales Volume by Company (tons) & (2021-2026) Table 8. Global Urology Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Urology Drugs Average Price (US$/kg) of Company (2021-2026) Table 10. Global Urology Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urology Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Urology Drugs Company, Product Type & Application Table 13. Global Urology Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Α (alpha) Blockers Table 18. Significant Companies of 5 α-reductase Inhibitors Table 19. Global Urology Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Urology Drugs Sales Volume by Type (2021-2026) & (tons) Table 21. Global Urology Drugs Sales Volume by Type (2027-2032) & (tons) Table 22. Global Urology Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Urology Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Urology Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Urology Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Urology Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Urology Drugs Sales Value Share by Type (2021-2026) Table 28. Global Urology Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Urology Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 33. Global Urology Drugs Sales Volume by Application (2021-2026) & (tons) Table 34. Global Urology Drugs Sales Volume by Application (2027-2032) & (tons) Table 35. Global Urology Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Urology Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Urology Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Urology Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Urology Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Urology Drugs Sales Value Share by Application (2021-2026) Table 41. Global Urology Drugs Sales Value Share by Application (2027-2032) Table 42. Global Urology Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 43. Global Urology Drugs Sales by Region (2021-2026) & (tons) Table 44. Global Urology Drugs Sales Market Share by Region (2021-2026) Table 45. Global Urology Drugs Sales by Region (2027-2032) & (tons) Table 46. Global Urology Drugs Sales Market Share by Region (2027-2032) Table 47. Global Urology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Urology Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Urology Drugs Sales Value Share by Region (2021-2026) Table 50. Global Urology Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Urology Drugs Sales Value Share by Region (2027-2032) Table 52. Global Urology Drugs Market Average Price (US$/kg) by Region (2021-2026) Table 53. Global Urology Drugs Market Average Price (US$/kg) by Region (2027-2032) Table 54. Global Urology Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Global Urology Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Urology Drugs Sales by Country (2021-2026) & (tons) Table 57. Global Urology Drugs Sales Market Share by Country (2021-2026) Table 58. Global Urology Drugs Sales by Country (2027-2032) & (tons) Table 59. Global Urology Drugs Sales Market Share by Country (2027-2032) Table 60. Global Urology Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Urology Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Urology Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Urology Drugs Sales Value Market Share by Country (2027-2032) Table 64. Endo Company Information Table 65. Endo Business Overview Table 66. Endo Urology Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 67. Endo Urology Drugs Product Portfolio Table 68. Endo Recent Development Table 69. Astellas Company Information Table 70. Astellas Business Overview Table 71. Astellas Urology Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 72. Astellas Urology Drugs Product Portfolio Table 73. Astellas Recent Development Table 74. Tolmar Company Information Table 75. Tolmar Business Overview Table 76. Tolmar Urology Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 77. Tolmar Urology Drugs Product Portfolio Table 78. Tolmar Recent Development Table 79. GP Pharm Company Information Table 80. GP Pharm Business Overview Table 81. GP Pharm Urology Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 82. GP Pharm Urology Drugs Product Portfolio Table 83. GP Pharm Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Urology Drugs Distributors List Table 87. Urology Drugs Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Urology Drugs Product Image Figure 2. Global Urology Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urology Drugs Sales (2021-2032) & (tons) Figure 5. Global Urology Drugs Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Urology Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Α (alpha) Blockers Image Figure 10. 5 α-reductase Inhibitors Image Figure 11. Global Urology Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Urology Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Urology Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Urology Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Urology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Urology Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Urology Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 21. Global Urology Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Urology Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Urology Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Urology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Urology Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Urology Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 27. Global Urology Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Urology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Urology Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Urology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Urology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Urology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Urology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Urology Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Urology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Urology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Urology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Urology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Urology Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Urology Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Α (alpha) Blockers
  • 5 α-reductase Inhibitors
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Endo
  • Astellas
  • Tolmar
  • GP Pharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urology Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Urology Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Urology Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urology Drugs Market Dynamics
  1. 2.1 Urology Drugs Industry Trends
  2. 2.2 Urology Drugs Industry Drivers
  3. 2.3 Urology Drugs Industry Opportunities and Challenges
  4. 2.4 Urology Drugs Industry Restraints
3 Urology Drugs Market by Company
  1. 3.1 Global Urology Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Urology Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Urology Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Urology Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Urology Drugs Company Ranking (2024-2026)
  6. 3.6 Global Urology Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Urology Drugs Company Product Type and Application
  8. 3.8 Global Urology Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urology Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urology Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urology Drugs Market by Type
  1. 4.1 Urology Drugs Type Introduction
  2. 4.1.1 Α (alpha) Blockers
  3. 4.1.2 5 α-reductase Inhibitors
  4. 4.2 Global Urology Drugs Sales Volume by Type
  5. 4.2.1 Global Urology Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urology Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Urology Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Urology Drugs Sales Value by Type
  9. 4.3.1 Global Urology Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urology Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Urology Drugs Sales Value Share by Type (2021-2032)
5 Urology Drugs Market by Application
  1. 5.1 Urology Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Urology Drugs Sales Volume by Application
  6. 5.2.1 Global Urology Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urology Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Urology Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Urology Drugs Sales Value by Application
  10. 5.3.1 Global Urology Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Urology Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Urology Drugs Sales Value Share by Application (2021-2032)
6 Urology Drugs Regional Sales and Value Analysis
  1. 6.1 Global Urology Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urology Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Urology Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Urology Drugs Sales by Region (2027-2032)
  5. 6.3 Global Urology Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urology Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urology Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urology Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Urology Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urology Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Urology Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urology Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Urology Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urology Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urology Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urology Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Urology Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urology Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urology Drugs Sales Value Share by Country, 2025 VS 2032
7 Urology Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Urology Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urology Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urology Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Urology Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Urology Drugs Sales by Country (2027-2032)
  6. 7.4 Global Urology Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urology Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urology Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urology Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urology Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urology Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urology Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urology Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urology Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urology Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urology Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urology Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urology Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urology Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urology Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urology Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urology Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urology Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urology Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urology Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urology Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urology Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urology Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urology Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urology Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urology Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urology Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urology Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urology Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urology Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urology Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urology Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urology Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urology Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urology Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urology Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urology Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urology Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urology Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urology Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urology Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urology Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urology Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urology Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urology Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urology Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urology Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urology Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urology Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urology Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urology Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urology Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urology Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urology Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urology Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urology Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urology Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urology Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urology Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urology Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urology Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urology Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urology Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urology Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urology Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urology Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urology Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urology Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urology Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urology Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urology Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urology Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urology Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urology Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urology Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urology Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urology Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urology Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urology Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urology Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urology Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urology Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urology Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urology Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urology Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urology Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urology Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Endo
  2. 8.1.1 Endo Company Information
  3. 8.1.2 Endo Business Overview
  4. 8.1.3 Endo Urology Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Endo Urology Drugs Product Portfolio
  6. 8.1.5 Endo Recent Developments
  7. 8.2 Astellas
  8. 8.2.1 Astellas Company Information
  9. 8.2.2 Astellas Business Overview
  10. 8.2.3 Astellas Urology Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Urology Drugs Product Portfolio
  12. 8.2.5 Astellas Recent Developments
  13. 8.3 Tolmar
  14. 8.3.1 Tolmar Company Information
  15. 8.3.2 Tolmar Business Overview
  16. 8.3.3 Tolmar Urology Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tolmar Urology Drugs Product Portfolio
  18. 8.3.5 Tolmar Recent Developments
  19. 8.4 GP Pharm
  20. 8.4.1 GP Pharm Company Information
  21. 8.4.2 GP Pharm Business Overview
  22. 8.4.3 GP Pharm Urology Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GP Pharm Urology Drugs Product Portfolio
  24. 8.4.5 GP Pharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urology Drugs Value Chain Analysis
  2. 9.1.1 Urology Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urology Drugs Sales Mode & Process
  6. 9.2 Urology Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urology Drugs Distributors
  9. 9.2.3 Urology Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst